



Korsana Biosciences Overview

July 2026

Disclaimers

The information contained in this presentation has been prepared by Korsana Biosciences, Inc. and its affiliates (“Korsana” or the “Company”) and contains information pertaining to the business and operations of the Company and the proposed reverse merger transaction with Cycleron Therapeutics, Inc. (“Cycleron”) and related pre-closing financing. The information contained in this presentation: (a) is provided as at the date hereof, is subject to change without notice, and is based on publicly available information, information obtained from third party sources, and internally developed data; (b) does not purport to contain all the information that may be necessary or desirable to fully and accurately evaluate an investment in the Company; (c) is not to be considered as a recommendation by the Company that any person make an investment in the Company; and (d) is for information purposes only. Where any opinion or belief is expressed in this presentation, it is based on certain assumptions and limitations and is an expression of present opinion or belief only. This presentation should not be construed as legal, financial, or tax advice to any individual, as each individual’s circumstances are different. This presentation shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the Company’s securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. Although the Company believes the third-party sources and publicly available information in this presentation to be reliable, it has not independently verified and makes no representation or warranty, express or implied, as to the accuracy, completeness or timeliness of any third-party data. Accordingly, no representation is made as to, and no reliance should be placed on, any third-party data contained in this presentation.

Forward-Looking Statements and Other Information

Certain information set forth in this presentation contains “forward-looking statements” within the meaning of applicable United States securities legislation. Except for statements of historical fact, certain information contained herein constitutes forward-looking statements which include but are not limited to statements regarding: our business strategy, including our ability to develop potentially best-in-class therapies initially focused on neurodegenerative disorders like Alzheimer’s disease, including a potentially best-in class shuttled anti-A β therapy offering meaningful improvements over trontinemab; the efficacy, safety profile, dosing regime, convenience, half-life, and tolerability of KRSA-028, including expectations regarding subcutaneous formulation, dosing volume, and projected human pharmacokinetics; Korsana’s ongoing and future clinical development activities, including the expected timing of CTN and IND filings, healthy volunteer PK and CSF data, and interim clinical proof of concept data for KRSA-028; the expected timing of unveiling additional THETA™ enabled programs; estimated market sizes, potential growth opportunities, potential value creation and comparable company valuations and deal economics; the anticipated growth of the Alzheimer’s therapeutics market and the expansion of the eligible patient population, including through presymptomatic indications and blood-based biomarker adoption; the length of time that the Company believes its existing cash resources will fund its operations, including expectations of cash runway extending into 2029; the proposed reverse merger transaction and related pre-closing financing, including the expected timing and completion thereof, estimated post-closing capitalization, and the expected ownership percentages of the combined company; and management’s assessment of future plans and operations which are based on current internal expectations, estimates, projections, assumptions and beliefs, which may prove to be incorrect. Forward-looking statements can often be identified by the use of words such as “may”, “will”, “could”, “would”, “anticipate”, “believe”, “expect”, “intend”, “potential”, “estimate”, “scheduled”, “plans”, “planned”, “forecasts”, “goals” and similar expressions or the negatives thereof. Forward-looking statements are neither historical facts nor assurances of future performance. Forward-looking statements are based on a number of factors and assumptions made by management and considered reasonable at the time such information is provided, and forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements, including: uncertainties and risks arising from regulatory feedback, including potential disagreement by regulatory authorities with our clinical trial design, interpretation of data and our ongoing or planned clinical trials for our product candidates; risks related to our patent portfolio and strategy, including our ability to obtain and protect patent rights or such rights being subject to challenges from third parties; risks related to the proposed reverse merger and pre-closing financing, including the possibility that the transactions may not be completed on the anticipated terms or timeline, or at all, and that the actual capitalization of the combined company may differ materially from the estimates presented herein; the expected or potential impact of macroeconomic conditions; the implementation of changes in law, tariffs, sanctions, export or import controls, and other government measures that could impact our business operations; the impacts of adverse events or disappointing results in clinical trials of third parties, including our competitors developing product candidates that target similar mechanisms of action and/or indications as our product candidates; and discussions of potential risks, uncertainties, and other filings by the Company from time to time, as well as risk factors associated with companies that operate in the biopharma industry, including those associated with the uncertainties of drug development. All of the forward-looking statements made in this presentation are qualified by these cautionary statements and other cautionary statements or other factors contained herein. Although management believes that the expectations conveyed by forward-looking statements herein are reasonable based on information available on the date such forward-looking statements are made, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company undertakes no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws. The forward-looking statements contained herein are presented for the purpose of assisting readers in understanding the Company’s plan, objectives, and goals and may not be appropriate for other purposes. The reader is cautioned not to place undue reliance on forward-looking statements.

Disclaimers

No Offer or Solicitation

This presentation and the information contained herein is not intended to and does not constitute (i) a solicitation of a proxy, consent or approval with respect to any securities or in respect of the proposed transactions or (ii) an offer to sell or the solicitation of an offer to subscribe for or buy or an invitation to purchase or subscribe for any securities pursuant to the proposed transactions or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. No offer of securities shall be made except in accordance with the requirements of the Securities Act of 1933, as amended, or an exemption therefrom. Subject to certain exceptions to be approved by the relevant regulators or certain facts to be ascertained, no public offer will be made directly or indirectly, in or into any jurisdiction where to do so would constitute a violation of the laws of such jurisdiction, or by use of the mails or by any means or instrumentality (including without limitation, facsimile transmission, telephone and the internet) of interstate or foreign commerce, or any facility of a national securities exchange, of any such jurisdiction.

NEITHER THE SEC NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THE SECURITIES OR DETERMINED IF THIS PRESENTATION IS TRUTHFUL OR COMPLETE.

Important Additional Information about the Proposed Transactions Will be Filed with the SEC

This presentation is not a substitute for the registration statement or for any other document that Cycleron may file with the SEC in connection with the proposed transactions. In connection with the proposed transactions between Cycleron and Korsana, Cycleron intends to file relevant materials with the SEC, including a registration statement on Form S-4 that will contain a proxy statement/prospectus of Cycleron. CYCLERION URGES INVESTORS AND SHAREHOLDERS TO READ THE REGISTRATION STATEMENT, PROXY STATEMENT/PROSPECTUS AND ANY OTHER RELEVANT DOCUMENTS THAT MAY BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY IF AND WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT CYCLERION, KORSANA, THE PROPOSED TRANSACTIONS AND RELATED MATTERS. Investors and shareholders will be able to obtain free copies of the proxy statement/prospectus and other documents filed by Cycleron with the SEC (when they become available) through the website maintained by the SEC at www.sec.gov. Shareholders are urged to read the proxy statement/prospectus and the other relevant materials when they become available before making any voting or investment decision with respect to the proposed transactions. In addition, investors and shareholders should note that Cycleron communicates with investors and the public using its website (www.cycleron.com).

Participants in the Solicitation

Cycleron, Korsana and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from shareholders in connection with the proposed transactions. Information about Cycleron's directors and executive officers, including a description of their interests in Cycleron, is included in Cycleron's most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q filed with the SEC, including any information incorporated therein by reference, as filed with the SEC, and other documents that may be filed from time to time with the SEC. Additional information regarding these persons and their interests in the transaction will be included in the proxy statement/prospectus relating to the proposed transactions when it is filed with the SEC. These documents can be obtained free of charge from the sources indicated above.

Korsana is developing potentially best-in-class therapies, with an initial focus on neurodegenerative disorders

- Initially focused on **potentially best-in-class therapies** for neurodegenerative disorders like Alzheimer's disease
- Built on **Therapeutic Targeting (THETA™)**, our next-generation BBB-penetrant shuttle platform
- Committed to **move fast** and develop a pipeline with **long-term defensibility**
- Proposed **reverse merger with Cycleron Therapeutics and concurrent \$380M private placement** expected to close in 3Q26, after which Korsana expected to trade on NASDAQ with ticker **KRSA**

Program	Indication	Stage	Mechanism of Action
KRSA-028	Alzheimer's disease	IND-enabling	Anti-3pE amyloid beta mAb (THETA-enabled)
Undisclosed	Undisclosed	Discovery	Undisclosed
Undisclosed	Undisclosed	Discovery	Undisclosed

Korsana is founded on four key beliefs



Alzheimer's is a vast and de-risked opportunity

*For the first time, there is a **validated, disease-modifying target for Alzheimer's** – but first-generation amyloid beta therapies leave **substantial room for improvement**.*



Shuttling is the best way to improve existing agents

*Transferrin receptor (TfR)-based shuttling is a de-risked modality to **increase brain penetration**; Roche's **trontinemab** has **provided proof-of-principle** in Alzheimer's disease.*



Korsana has the potential best-in-class approach

*Lead program KRSA-028 is potentially **superior to trontinemab**, and we are **advancing multiple next-generation programs**.*



Korsana has a rapid path to value creation


*KRSA-028 development can be **highly de-risked in Phase 1**, as amyloid clearance is proven to translate to clinical benefit – creating **significant early value inflection**.*



**Alzheimer's is a vast
and de-risked opportunity**

Alzheimer's is a devastating neurological disorder with significant unmet need and a rapidly growing patient population

The number of Americans with Alzheimer's is **projected to nearly double** by 2050






Alzheimer's disease is a **massive and growing unmet need**, with associated long-term healthcare costs projected to be **>\$1T by 2050**.

Despite clinical progress and approvals, today's anti-A β therapies leave significant room for improvement


Approved therapies only demonstrate **~30% slowing of disease progression** at 18 months...

...and carry **black box warnings for ARIA risk**, affecting **~15-25%** of treated patients




Although these therapies are disease-modifying, patients **still experience progression**, with potential for **new therapies to deliver superior efficacy and safety**.

Approved therapies are also highly inconvenient, with onerous IV dosing and MRI monitoring on label



First-gen therapies have laid out the roadmap for success: amyloid reduction predicts slowing of cognitive decline



*“The Agency has found... that **reduction of brain A β plaque on PET** is reasonably likely to predict clinical benefit in Alzheimer’s disease.”*

– Donanemab FDA Review

*“It is reasonable to conclude that **treatment that is targeted at reducing amyloid plaque**, and that successfully accomplishes that reduction, **has the potential to convey clinical benefit.**”*


– Lecanemab FDA Review

The field now has a **well-trodden path to regulatory success** for anti-amyloid beta therapies, with risk **discharged early in clinical development** with a validated biomarker.



**Shuttling is the best way
to improve existing agents**


Shuttling approaches actively ferry large molecules across the blood-brain barrier (BBB), fundamentally changing CNS penetration



Roche's trontinemab, the first shuttled anti-A β antibody, has shown a significant efficacy improvement over first-gen gantenerumab...


Trontinemab shows **~8x increased CSF exposure** over gantenerumab in humans...

CSF to plasma ratio (%)



... and most trontinemab-treated Alzheimer's patients reached **"amyloid-negative" status** by W28


Amyloid PET (centiloids)



Notes: CSF: cerebrospinal fluid. Roche CSF data digitized from AD/PD presentation and represents Roche's own cross-trial comparison, with trontinemab CSF to plasma ratio from single-dose IV study compared to historical data from a prior gantenerumab SAD trial. Amyloid reduction is a cross-trial comparison. Gantenerumab dosing titrates up to 510 mg Q2W maintenance dosing. 0 CL anchored on "high certainty" young, healthy controls & 100 CL anchored on typical AD patients. A threshold of 24.1 CL discriminates sparse from moderate plaque presence and is generally viewed as the cutoff for classifying patients as "amyloid negative." Sources: 2021 Kulic (AD/PD Presentation); 2023 Bateman (NEJM); 2025 Kulic (AAIC Presentation), 2025 Klein (AAIC Presentation).

... and greatly reduces ARIA, the critical safety signal for this class of therapies

ARIA rate (%)




Notes: Comparisons are across trials with different patient populations and trial designs, including study duration. No head-head-to-head comparison studies have been conducted. Trontinemab values include placebo patients (patients were randomized 4:1); N otherwise refers to patients on drug. ARIA: amyloid-related imaging abnormality; ARIA-E: edema and effusion; ARIA-H: microhemorrhage.
Sources: 2023 Bateman (NEJM); 2022 van Dyck (NEJM); 2023 Sims (JAMA) 2025 Kulic (AAIC Presentation)

However, as a first-gen shuttled A β , trontinemab's profile leaves substantial headroom for competitive differentiation

Efficacy


Mean amyloid plaque reductions from baseline



No evidence that maximum efficacy was reached in Phase 2 dose-response; further room to improve on trontinemab efficacy ¹

Safety

Mean hemoglobin changes from baseline



Trontinemab's full effector function leads to reticulocyte destruction, with **decreased hemoglobin** and **10-20% rates of clinical anemia** observed in Phase 2 ¹

Dosing & Tolerability

Incidence of infusion related reactions

Treatment emergent AEs: infusion-related reactions (IRRs)

IRRs are common and generally mild-to-moderate in severity

1.8 mg/kg or placebo	50% N=38 of 76
3.6 mg/kg or placebo	44% N=33 of 75


Trontinemab requires **IV dosing** and is associated with a **high rate of infusion-related reactions**, even with steroid pre-medication ²



**Korsana has the potential
best-in-class approach**

Korsana's goal is to achieve a best-in-class shuttled A β therapy, offering meaningful improvements over trontinemab

Key Value Drivers for KRSA-028



**FAST, ROBUST
AMYLOID REDUCTIONS**

➤ Efficacy on par or greater than trontinemab



**DIFFERENTIATED
SAFETY PROFILE**

➤ Minimal ARIA risk, avoid hematologic AEs



**CONVENIENT,
PATIENT-FRIENDLY DOSING**

➤ Low-volume subcutaneous autoinjector for infrequent dosing (Q4W or less)

KRSA-028 is a next-gen, potentially best-in-class shuttled anti-A β

Pyroglutamate-A β targeted backbone

- Targets the A β epitope associated with the **greatest amyloid plaque clearance** in clinical studies
- **Preferential, high-affinity binding to amyloid plaques**

Proprietary Fc engineering

- Leverages clinically validated **half-life extension** to reduce dosing frequency
- Selective **effector function modulation** designed to maintain amyloid plaque clearance by phagocytosis while **reducing complement activation and risk of anemia**

Subcutaneous formulation


- Expected to be **efficacious at lower dose** than first-generation shuttled therapies
- Optimized for **low volume monthly SC dosing**, with high concentration and low viscosity

Validated shuttle targeting


- Novel sequence leverages proven TfR1 target and epitope, designed to **improve brain penetration** and **reduce ARIA risk**

Enabled by **Therapeutic Targeting (THETA™)**

- Precision-engineered for **optimized half-life, distribution, and effector function**
- Proprietary combination of clinically validated technologies offers **de-risked differentiation**



Targeting the plaque-specific pyroglu-Aβ epitope has been shown to deliver the most promising clinical efficacy in Phase 3 trials



Antibody	Aβ epitope / species targeted
Donanemab	3pE (pyroglutamate) / plaques
Aducanumab	Oligomers, protofibrils, fibrils, plaques
Lecanemab	Oligomers, protofibrils, fibrils
Gantenerumab	Oligomers, protofibrils, fibrils, plaques
Crenezumab	Monomers, oligomers, fibrils, plaques <i>Fc-null – no phagocytosis</i>
Solanezumab	Primarily monomers

Note: Remternetug (not shown) is Lilly’s follow-on program to donanemab and also targets pyroglu-Aβ epitope; Phase 3 trial is ongoing

KRSA-028 targets plaque-selective pyroglu-A β to maximize plaque clearance through phagocytosis


KRSA-028 A β backbone:

- Same **plaque-selective epitope** as donanemab and remternetug
- **High A β affinity**, $K_D = 17$ nM
- **Potent phagocytosis (ADCP)**, $EC_{50} = 0.21$ nM

Donanemab (Kisunla) is the only approved Alzheimer's treatment that targets 3pE-A β , but it features high immunogenicity and ARIA.

Remternetug is Lilly's follow-on program to donanemab with reduced immunogenicity, currently in Ph3 as a subcutaneous treatment.


KRSA-028 exhibits potent pyroglu-A β phagocytosis




Representative plot shows mean $\pm$ SD, n=3 replicates. 20 μ g/mL pHrodo-red labeled 3pE-A β fibrils incubated 24 hrs with activated monocytes (U937 cells)

KRSA-028 has a longer half-life than trontinemab and avoids reticulocyte depletion in NHPs

KRSA-028 has >2.5x half-life in NHPs compared to trontinemab




KRSA-028 avoids reticulocyte depletion in NHPs




KRSA-028 shows improved brain penetration in mouse and NHP

KRSA-028 demonstrates increased brain penetration in hTfR1/hFcRn mouse model




KRSA-028 shows >6x brain penetration in NHPs compared to trontinemab



Data are mean $\pm$ SD. Values below 5 ng/mg (mice) and 1.25 ng/mg (NHP) are estimates as concentrations are below lower limit of quantitation. All compounds were dosed as a single dose (n=3/group). Mice and NHPs were dosed KRSA-028 equimolar to 10 mg/kg trontinemab. Non-shuttled mAb (remternetug) chosen as negative control and dosed at 20 mg/kg. NHP brain PK is an average of concentrations (separately analyzed) from frontal cortex, caudate, putamen, temporal cortex, hippocampus, and cerebellum. Data only collected for first two timepoints for non-shuttled mAb.

KRSA-028 is expected to match trontinemab Phase 3 IV exposure with low volume SC, compatible with autoinjector



Note: 250 mg trontinemab corresponds to the Ph3 dose of 3.6 mg/kg for average weight of 70 kg; model assumes 50% bioavailability

- PK model suggests that KRSA-028 will match trontinemab Phase 3 exposure with a **monthly SC volume of 1-2 mL**
- Initial KRSA-028 formulation achieved **150mg/mL with low viscosity**, compatible with autoinjector development
- **High stability** in human serum and in NHP
- Robust early formulation stress-test results **de-risk SC development pathway**
- Korsana plans to **initiate clinical development with SC dosing**

We believe KRSA-028 preclinical data accelerate & de-risk development

Precision engineered for a differentiated therapeutic profile


- **Novel A β and TfR1 binding sequences** retain key features of clinically validated molecules
- **High affinity pyroglu-A β binding** and clearance via ADCP leverage best-proven mechanism of efficacy
- **TfR1 binding matches trontinemab epitope with similar affinity**, leveraging the best-proven mechanism of brain distribution
- **Clinically validated Fc modifications** add half-life extension and effector function modulation to enable a lower dose and reduce anemia risk
- **Early formulation work supports high concentration, low viscosity** to enable low-volume SC
- **Composition of matter** patent applications filed




**»»» Korsana has a rapid path
to value creation**

PET imaging in early clinical development provides rapid proof of concept and dose-ranging for amyloid plaque clearing

Trontinemab Phase 1/2: Robust dose-response by Day 50



Remternetug Phase 1: Robust dose-response by Day 85



We believe **KRSA-028 amyloid PET data** – achievable in a **Phase 1/1b trial** – should provide high confidence in **predicting Phase 3 CDR-SB**, the endpoint for full approval.

A confluence of scientific innovations and market dynamics are driving Alzheimer's treatment to a major inflection point

Despite a slower than expected launch, sales of A β therapies are accelerating

- Improved dose regimens (SC, dose titration)
- Blood-based biomarkers are gaining traction
- Increasing footprint of global approvals
- Future entrants (e.g., trontinemab) will further grow market

Sales expected to reach \$1B in 2026, \$5B+ by 2030

Upcoming catalysts in presymptomatic AD may lead to rapid market expansion

- Donanemab TRAILBLAZER-ALZ 3 (~2027)
- Lecanemab AHEAD 3-45 (~2028)
- Remternetug TRAILRUNNER-ALZ 3 (~2029)
- Trontinemab PreventRON (study start 2026)

Data could greatly expand eligible patient pool


The future of Alzheimer's treatment will center on a **prevention-based paradigm**, where patients are **diagnosed before symptom onset** and given a **safe, convenient A β plaque-clearing therapy**.

KRSA-028 Phase 1/2 trial: designed to rapidly deliver potentially differentiating data

Trial design: Single Ascending Dose in healthy volunteers, with integrated Multiple Ascending Dose in Alzheimer's disease patients, and expansion cohorts designed to enable Phase 3



Korsana is well-funded through multiple clinical milestones



Strong cash position of ~\$475M¹ supports KRSA-028 Phase 3 readiness as well pipeline expansion, with runway into 29

Korsana is poised for rapid progress

Near-Term Catalysts

KRSA-028

- **CTN filing expected YE26**
- IND filing expected 1Q27
- Healthy volunteer **PK & CSF data expected Mid-Year 27**
- **Interim clinical PoC data in Alzheimer's patients expected by YE27-1Q28**

Continued advancement of Alzheimer's field likely to solidify Korsana opportunity

Pipeline

- Unveiling **additional THETA™ enabled programs** in 2026-27

Focused on diseases with high unmet need where shuttling could drive best-in-class profile

Well-Financed

- **\$25M** seed round Q4 2024
- **\$150M** Series A Sept 2025
- **\$380M** PIPE, expected to close in 3Q26 alongside merger with CYCN
- **Cash runway into 2029** after expected PIPE close

Strong Comps

- Rapid path to compelling PoC clinical data, comparable to multi-\$B public and M&A valuations (e.g., Aliada Ph1, Alpine Ph1/2, Avidity Ph2)

Experienced Leadership

- Seasoned **CEO Jonathan Violin**
 - Prior CEO roles include: Viridian Therapeutics, Dianthus Therapeutics, Quellis Biosciences
- Discovery programs led by **Paragon Therapeutics**
- Board of Directors comprised of **leading biotech investors**
 - Tomas Kiselak (Chair), Fairmount
 - Andrew Gottesdiener, Venrock
 - Michelle Pernice, Fairmount
 - Nimish Shah, Venrock

Estimated capitalization following close of reverse merger & pre-closing financing

		Shares on an as-converted basis	Expected ownership of the combined company
CYCLERION THERAPEUTICS	Shares of common stock outstanding (including underlying options, preferred & RSAs)	4,681,351	1.1%
KORSANA BIOSCIENCES	- Shares of common stock outstanding (including underlying options and warrants) - Preferred stock	61,721,199 140,719,246	45.5%
PRE-CLOSING FINANCING	Shares of common stock and PFWs	237,921,934	53.4%
Estimated total shares of common stock of the combined company post-closing		445,043,730	



Thank you